# Richard P. Baum

Source: https://nuclide.cc/people/richard-baum/  
Nuclide record `richard-baum` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.

## Summary

Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-17
- Tags: leadership
- Role: Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt
- Specialisms: Nuclear medicine; Peptide receptor radionuclide therapy; PSMA radioligand therapy; Theranostics

## Sources

- Curanosticum: https://www.curanosticum.de/en/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [Lutetium-177 radioligand therapy](https://nuclide.cc/technologies/lu177-radioligand-therapy/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- institutions: [Curanosticum Wiesbaden-Frankfurt](https://nuclide.cc/institutions/curanosticum/)
- pairings: [68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)](https://nuclide.cc/pairings/ga68-dotatate-then-lutathera/)
- key papers: [Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate](https://nuclide.cc/key-papers/paper-strosberg-netter1-qol-jco-2018/), [Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms](https://nuclide.cc/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/)
- people: [Michael Lassmann](https://nuclide.cc/people/michael-lassmann/)

---
JSON: https://nuclide.cc/api/v1/entities/richard-baum.json